These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 32772795)

  • 1. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
    Cosimati A; Rossi L; Didona D; Forcella C; Didona B
    J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S; Nguyen R; Opie JM; Andrews MC
    Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
    Lopez AT; Geskin L
    Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.
    Adachi E; Honda T; Nonoyama S; Irie H; Yamamura K; Otsuka A; Kabashima K
    J Dermatol; 2019 Jul; 46(7):e232-e233. PubMed ID: 30758879
    [No Abstract]   [Full Text] [Related]  

  • 5. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report.
    Muto Y; Namikawa K; Fujiwara Y; Mori T; Nakano E; Takahashi A; Yamazaki N
    J Dermatol; 2020 Jan; 47(1):e9-e11. PubMed ID: 31674068
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bullous pemphigoid induced by cancer immunotherapy].
    Giroud S; Chiticariu-Durr E
    Rev Med Suisse; 2020 Apr; 16(688):624-628. PubMed ID: 32239835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy.
    Guan S; Zhang L; Zhang J; Song W; Zhong D
    Front Immunol; 2022; 13():1068978. PubMed ID: 36685586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.
    Schwartzman G; Simpson MM; Jones R; Schiavone K; Coffman M; Meyerle J
    Cutis; 2020 Jun; 105(6):E9-E12. PubMed ID: 32716997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid.
    Zhang X; Sui D; Wang D; Zhang L; Wang R
    Front Immunol; 2021; 12():731774. PubMed ID: 34594337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
    Aggarwal P
    Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
    [No Abstract]   [Full Text] [Related]  

  • 11. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
    Wada N; Uchi H; Furue M
    J Dermatol; 2017 Oct; 44(10):e240-e241. PubMed ID: 28677843
    [No Abstract]   [Full Text] [Related]  

  • 12. A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication.
    Bezinelli LM; Eduardo FP; Migliorati CA; Ferreira MH; Taranto P; Sales DB; Santi CG; Macarenco RS; Godoy CPV; Corrêa L; Buzaid AC
    J Immunother; 2019; 42(9):359-362. PubMed ID: 31246641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.
    Carlos G; Anforth R; Chou S; Clements A; Fernandez-Peñas P
    Melanoma Res; 2015 Jun; 25(3):265-8. PubMed ID: 25831416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
    Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
    Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report.
    Pop SR; Strock D; Smith RJ
    Dermatol Ther; 2022 Aug; 35(8):e15623. PubMed ID: 35669992
    [No Abstract]   [Full Text] [Related]  

  • 16. Pembrolizumab-induced reactivation of bullous pemphigoid.
    Kaul S; Wang A; Grushchak S; Albrecht J
    Int J Dermatol; 2021 Jun; 60(6):757-758. PubMed ID: 33615441
    [No Abstract]   [Full Text] [Related]  

  • 17. Cutaneous metastases at the sites of pembrolizumab-induced bullous pemphigoid lesions in a patient with melanoma.
    Ványai B; Chien YC; Beke L; Szabó IL; Péter Z; Steuer-Hajdu K; Várvölgyi T; Méhes G; Emri G
    Immunotherapy; 2022 Dec; 14(17):1377-1382. PubMed ID: 36475303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient.
    Gorospe L; García-Gómez-Muriel I; Pian-Arias HG; Gómez-Ramírez J; Rioja-Martín ME; Olmedo-García ME; Garrido-López P; Muñoz-Molina GM; Mezquita L
    Ann Thorac Surg; 2020 Jun; 109(6):e397-e399. PubMed ID: 31846639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab-induced lichen planus pemphigoides in a patient with metastatic non-small-cell lung cancer.
    Senoo H; Kawakami Y; Yokoyama E; Yamasaki O; Morizane S
    J Dermatol; 2020 Apr; 47(4):e121-e122. PubMed ID: 31984550
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.
    Huynh LM; Bonebrake BT; DiMaio DJ; Baine MJ; Teply BA
    Medicine (Baltimore); 2021 Dec; 100(49):e28199. PubMed ID: 34889301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.